NovaTarg’s cell-based screening platform identifies tissue-selective drug candidates, including lead compound NT1195, which has been designed to treat T2D patients with impaired renal function

We have created a library of over 260 novel biguanides and have screened them for functional activity in cells expressing 1 of 6 organic cation transporters (OCT1-3, MATE1, PMAT and OCTN1).

Data generated from this screening process has been used to guide the selection of tissue-specific AMPK activators.